Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganaxolone in PCDH19 and Rare Genetic Epilepsies
NCT02358538Phase 2Completed
- Sponsor
- Marinus Pharmaceuticals
- Start
- Nov 2015
- Primary completion
- Jan 2018
- Modality
- Allosteric Modulators
- Countries
- 2
01
Overview
A Phase 2 trial of ganaxolone in PCDH19 clustering epilepsy (DEE9), CDKL5 deficiency disorder (CDD), Dravet syndrome, Lennox-Gastaut syndrome (LGS), Continuous Spikes And Waves During Sleep Syndrome (CSWS), sponsored by Marinus Pharmaceuticals. Started Nov 2015; status: completed.
02
Drugs
ganaxolone
03
Conditions
PCDH19 clustering epilepsy (DEE9)CDKL5 deficiency disorder (CDD)Dravet syndromeLennox-Gastaut syndrome (LGS)Continuous Spikes And Waves During Sleep Syndrome (CSWS)
Beyond the preview
Go deeper on NCT02358538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02358538.